Inovio Pharma (INO) Misses Q4 EPS by 14c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
March 12, 2020 4:05 PM EDTPLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ --Â INOVIO Pharmaceuticals, Inc. (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases, today reported financial results for the fourth quarter and year ended December 31, 2019. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update.
INOVIO Highlights
VGX-3100: Cervical, vulvar, and anal HSIL
REVEAL 2 Phase 3 clinical trial... More
